Novartis (NVS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NVS Stock Forecast

Novartis stock forecast is as follows: an average price target of $120.50 (represents a 24.52% upside from NVS’s last price of $96.77) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

NVS Price Target

The average price target for Novartis (NVS) is $120.50 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $121.00 to $120.00. This represents a potential 24.52% upside from NVS's last price of $96.77.

NVS Analyst Ratings

Hold

According to 9 Wall Street analysts, Novartis's rating consensus is 'Hold'. The analyst rating breakdown for NVS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (33.33%), 6 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Novartis Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 30, 2024	Etzer Darout	BMO Capital	$120.00	$109.91	9.18%	24.01%
Sep 05, 2024	James Quigley	Goldman Sachs	$121.00	$119.38	1.36%	25.04%
Jul 19, 2024	Etzer Darout	BMO Capital	$118.00	$106.13	11.18%	21.94%
Apr 23, 2024	Wan Nurhayati	CFRA	$108.00	$97.27	11.03%	11.60%

The latest Novartis stock forecast, released on Oct 30, 2024 by Etzer Darout from BMO Capital, set a price target of $120.00, which represents a 9.18% increase from the stock price at the time of the forecast ($109.91), and a 24.01% increase from NVS last price ($96.77).

Novartis Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$120.00	$116.75
Last Closing Price	$96.77	$96.77	$96.77
Upside/Downside	-100.00%	24.01%	20.65%

In the current month, the average price target of Novartis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Novartis's last price of $96.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	BMO Capital	Market Perform	Market Perform	Hold
Sep 05, 2024	Goldman Sachs	Buy	Neutral	Downgrade
Sep 02, 2024	Jefferies	Buy	Hold	Downgrade
Jul 19, 2024	BMO Capital	Market Perform	Market Perform	Hold
Jul 19, 2024	Deutsche Bank		Hold	Downgrade
Jul 12, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Jul 11, 2024	Oddo BHF		Outperform	Upgrade
Jul 02, 2024	Jefferies	Buy	Buy	Hold
May 30, 2024	Goldman Sachs		Buy	Initialise
Apr 24, 2024	UBS	Buy	Buy	Hold
Apr 23, 2024	CFRA	Hold	Hold	Hold
Aug 24, 2023	William Blair	Outperform	Outperform	Hold

Novartis's last stock rating was published by BMO Capital on Oct 30, 2024. The company gave NVS a "Market Perform" rating, the same as its previous rate.

Novartis Financial Forecast

Novartis Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	-	$13.21B	$13.09B	$12.84B	$13.09B	$12.81B	$13.52B	$13.37B	$13.29B	$12.69B	$13.03B	$12.54B	$11.62B	$12.71B	$12.72B	$12.48B	$12.02B	$11.46B	$12.93B	$11.79B
Avg Forecast	$12.25B	$12.85B	$13.07B	$12.67B	$12.99B	$12.79B	$12.45B	$11.44B	$11.88B	$12.42B	$13.47B	$12.72B	$13.22B	$12.88B	$12.88B	$12.62B	$13.33B	$13.06B	$12.55B	$12.50B	$12.90B	$12.60B	$11.84B	$12.00B	$12.33B	$11.70B	$11.49B	$11.09B	$12.93B	$11.57B
High Forecast	$12.39B	$13.00B	$13.23B	$12.88B	$13.24B	$12.86B	$12.49B	$11.44B	$12.25B	$12.65B	$13.63B	$12.86B	$13.37B	$12.88B	$12.88B	$12.62B	$13.33B	$13.06B	$12.55B	$12.50B	$12.90B	$12.60B	$11.84B	$12.00B	$12.33B	$11.70B	$11.49B	$11.09B	$15.51B	$13.89B
Low Forecast	$12.11B	$12.70B	$12.92B	$12.46B	$12.82B	$12.72B	$12.41B	$11.44B	$11.59B	$12.28B	$13.32B	$12.57B	$13.06B	$12.88B	$12.88B	$12.62B	$13.33B	$13.06B	$12.55B	$12.50B	$12.90B	$12.60B	$11.84B	$12.00B	$12.33B	$11.70B	$11.49B	$11.09B	$10.34B	$9.26B
# Analysts	1	1	1	1	3	1	2	2	4	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	8	8	8	8	10	17
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.04%	0.99%	1.00%	1.02%	1.02%	1.01%	1.02%	1.06%	1.02%	1.01%	0.99%	0.98%	1.06%	1.03%	1.07%	1.05%	1.03%	1.00%	1.02%

Novartis's average Quarter revenue forecast for Jun 23 based on 1 analysts is $13.47B, with a low forecast of $13.32B, and a high forecast of $13.63B. NVS's average Quarter revenue forecast represents a 2.02% increase compared to the company's last Quarter revenue of $13.21B (Mar 23).

Novartis EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	2	2	4	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	8	8	8	8	10	17
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$4.95B	$3.91B	$4.16B	$4.05B	$4.28B	$18.68B	$4.88B	$5.15B	$4.35B	$4.37B	$4.36B	$4.21B	$4.27B	$3.90B	$4.03B	$8.57B	$3.71B	$2.63B	$3.90B
Avg Forecast	$3.95B	$4.15B	$4.22B	$4.09B	$4.19B	$4.13B	$4.02B	$5.18B	$3.84B	$4.01B	$4.35B	$4.71B	$4.27B	$5.16B	$5.16B	$4.28B	$5.34B	$5.23B	$5.03B	$4.54B	$5.17B	$5.05B	$4.74B	$3.68B	$4.94B	$4.69B	$4.60B	$3.55B	$2.63B	$3.83B
High Forecast	$4.00B	$4.19B	$4.27B	$4.16B	$4.27B	$4.15B	$4.03B	$6.21B	$3.95B	$4.08B	$4.40B	$5.65B	$4.32B	$5.16B	$5.16B	$5.13B	$5.34B	$5.23B	$5.03B	$5.45B	$5.17B	$5.05B	$4.74B	$4.42B	$4.94B	$4.69B	$4.60B	$4.25B	$3.16B	$4.60B
Low Forecast	$3.91B	$4.10B	$4.17B	$4.02B	$4.14B	$4.11B	$4.01B	$4.14B	$3.74B	$3.96B	$4.30B	$3.76B	$4.22B	$5.16B	$5.16B	$3.42B	$5.34B	$5.23B	$5.03B	$3.63B	$5.17B	$5.05B	$4.74B	$2.94B	$4.94B	$4.69B	$4.60B	$2.84B	$2.10B	$3.07B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.05%	0.92%	0.81%	0.78%	1.00%	3.50%	0.93%	1.02%	0.96%	0.85%	0.86%	0.89%	1.16%	0.79%	0.86%	1.86%	1.05%	1.00%	1.02%

1 analysts predict NVS's average Quarter EBITDA for Jun 23 to be $4.35B, with a high of $4.40B and a low of $4.30B. This is -12.09% lower than Novartis's previous annual EBITDA (Mar 23) of $4.95B.

Novartis Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	2	2	4	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	8	8	8	8	10	17
Net Income	-	-	-	-	-	-	-	-	-	-	-	$2.29B	$1.47B	$1.57B	$1.69B	$2.22B	$16.31B	$2.76B	$2.90B	$2.06B	$2.09B	$1.94B	$1.87B	$2.18B	$1.13B	$2.04B	$6.80B	$1.77B	$2.02B	$1.67B
Avg Forecast	$4.09B	$4.29B	$4.45B	$4.01B	$3.70B	$3.93B	$3.75B	$2.69B	$3.35B	$3.38B	$3.32B	$2.44B	$18.44B	$3.01B	$2.92B	$2.22B	$2.75B	$3.17B	$3.02B	$2.15B	$2.65B	$2.80B	$2.57B	$1.87B	$2.55B	$2.57B	$2.35B	$1.69B	$2.02B	$1.64B
High Forecast	$4.15B	$4.35B	$4.52B	$4.15B	$3.92B	$3.95B	$3.75B	$3.23B	$3.61B	$3.43B	$3.37B	$2.93B	$22.12B	$3.01B	$2.92B	$2.67B	$2.75B	$3.17B	$3.02B	$2.58B	$2.65B	$2.80B	$2.57B	$2.25B	$2.55B	$2.57B	$2.35B	$2.03B	$2.43B	$1.96B
Low Forecast	$4.03B	$4.22B	$4.38B	$3.85B	$3.54B	$3.91B	$3.75B	$2.15B	$3.13B	$3.36B	$3.27B	$1.96B	$14.75B	$3.01B	$2.92B	$1.78B	$2.75B	$3.17B	$3.02B	$1.72B	$2.65B	$2.80B	$2.57B	$1.50B	$2.55B	$2.57B	$2.35B	$1.35B	$1.62B	$1.31B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.94%	0.08%	0.52%	0.58%	1.00%	5.93%	0.87%	0.96%	0.96%	0.79%	0.69%	0.73%	1.16%	0.44%	0.79%	2.90%	1.05%	1.00%	1.02%

Novartis's average Quarter net income forecast for Jun 23 is $3.32B, with a range of $3.27B to $3.37B. NVS's average Quarter net income forecast represents a 44.91% increase compared to the company's last Quarter net income of $2.29B (Mar 23).

Novartis SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	2	2	4	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	8	8	8	8	10	17
SG&A	-	-	-	-	-	-	-	-	-	-	-	$3.44B	$3.75B	$3.41B	$3.58B	$3.51B	$3.98B	$3.62B	$3.75B	$3.53B	$3.92B	$3.42B	$3.37B	$3.49B	$3.90B	$3.55B	$3.58B	$3.33B	$3.92B	$3.47B
Avg Forecast	$3.44B	$3.61B	$3.67B	$3.56B	$3.65B	$3.59B	$3.50B	$4.25B	$3.34B	$3.49B	$3.78B	$3.86B	$4.51B	$3.62B	$3.62B	$3.51B	$3.74B	$3.67B	$3.53B	$3.68B	$3.62B	$3.54B	$3.33B	$3.00B	$3.46B	$3.29B	$3.23B	$3.19B	$3.92B	$3.41B
High Forecast	$3.48B	$3.65B	$3.71B	$3.62B	$3.72B	$3.61B	$3.51B	$5.10B	$3.44B	$3.55B	$3.83B	$4.64B	$5.41B	$3.62B	$3.62B	$4.21B	$3.74B	$3.67B	$3.53B	$4.42B	$3.62B	$3.54B	$3.33B	$3.60B	$3.46B	$3.29B	$3.23B	$3.82B	$4.71B	$4.09B
Low Forecast	$3.40B	$3.57B	$3.63B	$3.50B	$3.60B	$3.57B	$3.48B	$3.40B	$3.25B	$3.45B	$3.74B	$3.09B	$3.60B	$3.62B	$3.62B	$2.81B	$3.74B	$3.67B	$3.53B	$2.95B	$3.62B	$3.54B	$3.33B	$2.40B	$3.46B	$3.29B	$3.23B	$2.55B	$3.14B	$2.73B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.89%	0.83%	0.94%	0.99%	1.00%	1.06%	0.99%	1.06%	0.96%	1.08%	0.97%	1.01%	1.16%	1.13%	1.08%	1.11%	1.05%	1.00%	1.02%

Novartis's average Quarter SG&A projection for Jun 23 is $3.78B, based on 1 Wall Street analysts, with a range of $3.74B to $3.83B. The forecast indicates a 9.88% rise compared to NVS last annual SG&A of $3.44B (Mar 23).

Novartis EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	2	2	4	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	8	8	8	8	10	17
EPS	-	-	-	-	-	-	-	-	-	-	-	$1.09	$0.69	$0.73	$0.77	$1.00	$7.29	$1.23	$1.29	$0.91	$0.92	$0.85	$0.82	$0.96	$0.50	$0.90	$2.94	$0.77	$0.87	$0.70
Avg Forecast	$2.02	$2.12	$2.20	$1.98	$1.83	$1.94	$1.85	$1.68	$1.65	$1.67	$1.64	$1.45	$1.35	$1.47	$1.43	$1.38	$1.34	$1.55	$1.47	$1.46	$1.30	$1.37	$1.26	$1.32	$1.25	$1.26	$1.15	$1.05	$1.28	$1.09
High Forecast	$2.05	$2.15	$2.23	$2.05	$1.93	$1.95	$1.85	$1.73	$1.78	$1.69	$1.66	$1.46	$1.37	$1.47	$1.43	$1.40	$1.34	$1.55	$1.47	$1.46	$1.30	$1.37	$1.26	$1.32	$1.25	$1.26	$1.15	$1.05	$1.54	$1.31
Low Forecast	$1.99	$2.08	$2.16	$1.90	$1.75	$1.93	$1.85	$1.63	$1.54	$1.66	$1.61	$1.44	$1.33	$1.47	$1.43	$1.35	$1.34	$1.55	$1.47	$1.46	$1.30	$1.37	$1.26	$1.32	$1.25	$1.26	$1.15	$1.05	$1.02	$0.87
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.75%	0.51%	0.50%	0.54%	0.73%	5.42%	0.79%	0.88%	0.62%	0.71%	0.62%	0.65%	0.73%	0.40%	0.72%	2.56%	0.73%	0.68%	0.64%

According to 1 Wall Street analysts, Novartis's projected average Quarter EPS for Jun 23 is $1.64, with a low estimate of $1.61 and a high estimate of $1.66. This represents a 50.39% increase compared to NVS previous annual EPS of $1.09 (Mar 23).

Novartis Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GSK	GSK	$34.23	$53.00	54.83%	Hold
MRK	Merck	$100.06	$135.83	35.75%	Buy
LLY	Eli Lilly and Company	$778.62	$1.03K	31.80%	Buy
AZN	AstraZeneca	$67.18	$88.00	30.99%	Buy
SNY	Sanofi	$48.94	$62.00	26.69%	Buy
PFE	Pfizer	$26.43	$32.83	24.21%	Hold
NVS	Novartis	$99.10	$120.50	21.59%	Hold
ABBV	AbbVie	$175.38	$211.20	20.42%	Buy
JNJ	Johnson & Johnson	$146.41	$175.13	19.62%	Buy
GILD	Gilead Sciences	$92.80	$87.30	-5.93%	Buy
BMY	Bristol-Myers Squibb Company	$57.65	$50.50	-12.40%	Hold

NVS Forecast FAQ

Is Novartis a good buy?

No, according to 9 Wall Street analysts, Novartis (NVS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 33.33% of NVS's total ratings.

What is NVS's price target?

Novartis (NVS) average price target is $120.5 with a range of $120 to $121, implying a 24.52% from its last price of $96.77. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Novartis stock go up soon?

According to Wall Street analysts' prediction for NVS stock, the company can go up by 24.52% (from the last price of $96.77 to the average price target of $120.5), up by 25.04% based on the highest stock price target, and up by 24.01% based on the lowest stock price target.

Can Novartis stock reach $150?

NVS's average twelve months analyst stock price target of $120.5 does not support the claim that Novartis can reach $150 in the near future.

What are Novartis's analysts' financial forecasts?

Novartis's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $49.67B (high $50.04B, low $49.39B), average EBITDA is $17.51B (high $18.67B, low $16.39B), average net income is $14.07B (high $14.85B, low $13.35B), average SG&A $14.98B (high $15.94B, low $14.05B), and average EPS is $7.29 (high $7.46, low $7.15). NVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.84B (high $51.49B, low $50.18B), average EBITDA is $16.41B (high $16.62B, low $16.2B), average net income is $16.84B (high $17.17B, low $16.48B), average SG&A $14.28B (high $14.46B, low $14.09B), and average EPS is $8.31 (high $8.47, low $8.13).

Did the NVS's actual financial results beat the analysts' financial forecasts?

Based on Novartis's last annual report (Dec 2022), the company's revenue was $51.83B, beating the average analysts forecast of $51.6B by 0.44%. Apple's EBITDA was $16.39B, missing the average prediction of $18.87B by -13.13%. The company's net income was $6.96B, missing the average estimation of $26.59B by -73.84%. Apple's SG&A was $14.25B, missing the average forecast of $15.25B by -6.56%. Lastly, the company's EPS was $3.19, missing the average prediction of $5.62 by -43.24%. In terms of the last quarterly report (Mar 2023), Novartis's revenue was $13.21B, beating the average analysts' forecast of $12.72B by 3.86%. The company's EBITDA was $4.95B, beating the average prediction of $4.71B by 5.13%. Novartis's net income was $2.29B, missing the average estimation of $2.44B by -6.19%. The company's SG&A was $3.44B, missing the average forecast of $3.86B by -10.88%. Lastly, the company's EPS was $1.09, missing the average prediction of $1.45 by -24.94%